{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T21:18:22Z","timestamp":1785705502250,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The ongoing debate regarding the need for screening Cushing\u2019s syndrome (CS) in patients with obesity continues. The objectives of this study were to establish the prevalence of CS in the population with obesity and assess how metabolic health status influences cortisol levels following the 1\u2009mg dexamethasone suppression test (DST).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study included 1008 patients with obesity who underwent screening with the 1\u2009mg DST for CS. These patients were categorized into two groups as metabolically healthy obesity (MHO) and unhealthy obesity (MUO).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of the 1008 patients, 779 (77.3%) belonged to the MUO group. Within the entire study cohort, 12 (1.2%) patients exhibited a cortisol level of \u2265 1.8 after the 1\u2009mg DST. Cortisol levels following the 1\u2009mg DST were also significantly higher in the MUO group than in the MHO group (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). Among these 12 patients, 11 were presenting a MUO phenotype. Hypercortisolism was definitively diagnosed in two patients, resulting in an overall prevalence of 0.2%. The 1\u2009mg DST demonstrated a specificity of 99% and 100% sensitivity for screening for CS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>While the 1\u2009mg DST is a practical screening test for CS with high specificity in obesity, the number of CS cases detected remains relatively low. Therefore, it may be more reasonable and applicable to screen patients with MUO phenotype rather than all individuals with obesity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41366-024-01598-0","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T11:21:02Z","timestamp":1723202462000},"page":"1620-1624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cushing\u2019s syndrome screening with the 1-mg dexamethasone suppression test in metabolically healthy and unhealthy obesity phenotypes"],"prefix":"10.1038","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8375-7409","authenticated-orcid":false,"given":"Sema","family":"Hepsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umran","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4957-9856","authenticated-orcid":false,"given":"Hayri","family":"Bostan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Akhanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Erkam","family":"Sencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Kizilgul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilknur Ozturk","family":"Unsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erman","family":"Cakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"1598_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jama.2023.11305","volume":"330","author":"M Reincke","year":"2023","unstructured":"Reincke M, Fleseriu M. Cushing syndrome. JAMA. 2023;330:170.","journal-title":"JAMA"},{"key":"1598_CR2","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1210\/clinem\/dgz136","volume":"105","author":"G Rubinstein","year":"2020","unstructured":"Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, Zacharieva S, et al. Time to diagnosis in Cushing\u2019s syndrome: a meta-analysis based on 5367 patients. J Clin Endocrinol Metab. 2020;105:e12\u201322.","journal-title":"J Clin Endocrinol Metab"},{"key":"1598_CR3","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526\u201340.","journal-title":"J Clin Endocrinol Metab"},{"key":"1598_CR4","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1053\/meta.2001.27213","volume":"50","author":"EAH Sims","year":"2001","unstructured":"Sims EAH. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50:1499\u2013504.","journal-title":"Metabolism"},{"key":"1598_CR5","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1001\/archinte.168.15.1609","volume":"168","author":"N Stefan","year":"2008","unstructured":"Stefan N. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609.","journal-title":"Arch Intern Med"},{"key":"1598_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S2213-8587(17)30292-9","volume":"6","author":"N Stefan","year":"2018","unstructured":"Stefan N, H\u00e4ring H-U, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol. 2018;6:249\u201358.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1598_CR7","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/oby.21442","volume":"24","author":"A Lammert","year":"2016","unstructured":"Lammert A, Nittka S, Otto M, Schneider-Lindner V, Kemmer A, Kr\u00e4mer BK, et al. Performance of the 1 mg dexamethasone suppression test in patients with severe obesity. Obesity. 2016;24:850\u20135.","journal-title":"Obesity"},{"key":"1598_CR8","first-page":"214","volume":"7","author":"RV Atar","year":"2020","unstructured":"Atar RV. The frequency of Cushing\u2019s disease, ACTH independent Cushing\u2019s syndrome, and autonomous cortisol secretion among Turkish patients with obesity. North Clin Istanb. 2020;7:214\u201321.","journal-title":"North Clin Istanb"},{"key":"1598_CR9","unstructured":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i\u2013xii, 1\u2013253."},{"key":"1598_CR10","doi-asserted-by":"publisher","first-page":"bnaa004","DOI":"10.1210\/endrev\/bnaa004","volume":"41","author":"M Bl\u00fcher","year":"2020","unstructured":"Bl\u00fcher M. Metabolically healthy obesity. Endocr Rev. 2020;41:bnaa004.","journal-title":"Endocr Rev"},{"key":"1598_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1210\/jc.2010-2722","volume":"96","author":"I Chiodini","year":"2011","unstructured":"Chiodini I. Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011;96:1223\u201336.","journal-title":"J Clin Endocrinol Metab"},{"key":"1598_CR12","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41574-024-00984-y","volume":"20","author":"A Prete","year":"2024","unstructured":"Prete A, Bancos I. Mild autonomous cortisol secretion: pathophysiology, comorbidities and management approaches. Nat Rev Endocrinol. 2024;20:460\u201373.","journal-title":"Nat Rev Endocrinol"},{"key":"1598_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11102-015-0634-9","volume":"18","author":"I Shimon","year":"2015","unstructured":"Shimon I. Screening for Cushing\u2019s syndrome: Is it worthwhile? Pituitary. 2015;18:201\u20135.","journal-title":"Pituitary"},{"key":"1598_CR14","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1210\/jc.2008-2766","volume":"94","author":"SK Baid","year":"2009","unstructured":"Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK. Specificity of screening tests for Cushing\u2019s syndrome in an overweight and obese population. J Clin Endocrinol Metab. 2009;94:3857\u201364.","journal-title":"J Clin Endocrinol Metab"},{"key":"1598_CR15","doi-asserted-by":"publisher","first-page":"e12358","DOI":"10.1111\/cob.12358","volume":"10","author":"TC Glyn","year":"2020","unstructured":"Glyn TC, Ho MW, Lambert AP, Thomas JDJ, Douek IF, Andrews RC, et al. Patients with morbid obesity should not be routinely screened for Cushing\u2019s syndrome: results of retrospective study of patients attending a specialist weight management service. Clin Obes. 2020;10:e12358.","journal-title":"Clin Obes"},{"key":"1598_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11695-011-0545-4","volume":"22","author":"D Jankovi\u0107","year":"2012","unstructured":"Jankovi\u0107 D, Wolf P, Anderwald C-H, Winhofer Y, Promintzer-Schifferl M, Hofer A, et al. Prevalence of endocrine disorders in morbidly obese patients and the effects of bariatric surgery on endocrine and metabolic parameters. Obes Surg. 2012;22:62\u20139.","journal-title":"Obes Surg"},{"key":"1598_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11695-010-0297-6","volume":"21","author":"P Fierabracci","year":"2011","unstructured":"Fierabracci P, Pinchera A, Martinelli S, Scartabelli G, Salvetti G, Giannetti M, et al. Prevalence of endocrine diseases in morbidly obese patients scheduled for bariatric surgery: beyond diabetes. Obes Surg. 2011;21:54\u201360.","journal-title":"Obes Surg"},{"key":"1598_CR18","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1007\/s11695-020-04865-x","volume":"30","author":"DG Yavuz","year":"2020","unstructured":"Yavuz DG, Apaydin T, Gunhan HG, Uygur MM. Assessment of 1 mg dexamethasone suppression test in patients with obesity before bariatric surgery. Obes Surg. 2020;30:4981\u20135.","journal-title":"Obes Surg"},{"key":"1598_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/S1807-59322010000100003","volume":"65","author":"O Tiryakioglu","year":"2010","unstructured":"Tiryakioglu O, Ugurlu S, Yalin S, Yirmibescik S, Caglar E, Yetkin DO, et al. Screening for Cushing\u2019s syndrome in obese patients. Clinics. 2010;65:9\u201313.","journal-title":"Clinics"},{"key":"1598_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1046\/j.1365-2265.1996.737558.x","volume":"44","author":"G Leibowitz","year":"1996","unstructured":"Leibowitz G, Tsur A, Chayen SD, Salameh M, Raz I, Cerasi E, et al. Pre-clinical Cushing\u2019s syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol. 1996;44:717\u201322.","journal-title":"Clin Endocrinol"},{"key":"1598_CR21","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1210\/jc.2009-2453","volume":"95","author":"K Mullan","year":"2010","unstructured":"Mullan K, Black N, Thiraviaraj A, Bell PM, Burgess C, Hunter SJ, et al. Is there value in routine screening for Cushing\u2019s syndrome in patients with diabetes? J Clin Endocrinol Metab. 2010;95:2262\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"1598_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1530\/eje.1.02045","volume":"153","author":"I Chiodini","year":"2005","unstructured":"Chiodini I, Torlontano M, Scillitani A, Arosio M, Bacci S, Di Lembo S, et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J Endocrinol. 2005;153:837\u201344.","journal-title":"Eur J Endocrinol"},{"key":"1598_CR23","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1210\/jc.2012-1323","volume":"97","author":"M Terzolo","year":"2012","unstructured":"Terzolo M, Reimondo G, Chiodini I, Castello R, Giordano R, Ciccarelli E, et al. Screening of Cushing\u2019s syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J Clin Endocrinol Metab. 2012;97:3467\u201375.","journal-title":"J Clin Endocrinol Metab"},{"key":"1598_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/00004872-199405000-00015","volume":"12","author":"GH Anderson","year":"1994","unstructured":"Anderson GH, Blakeman N, Streeten DHP. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609.","journal-title":"J Hypertens"},{"key":"1598_CR25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1097\/HJH.0b013e3283521484","volume":"30","author":"LC Martins","year":"2012","unstructured":"Martins LC, Concei\u00e7\u00e3o FL, Muxfeldt ES, Salles GF. Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension. J Hypertens. 2012;30:967\u201373.","journal-title":"J Hypertens"},{"key":"1598_CR26","first-page":"108","volume":"8","author":"R Trifanescu","year":"2013","unstructured":"Trifanescu R, Carsote M, Caragheorgheopol A, Hortopan D, Dumitrascu A, Dobrescu M, et al. Screening for secondary endocrine hypertension in young patients. Maedica. 2013;8:108\u201315.","journal-title":"Maedica"},{"key":"1598_CR27","doi-asserted-by":"publisher","first-page":"e3723","DOI":"10.1210\/clinem\/dgac379","volume":"107","author":"LT Braun","year":"2022","unstructured":"Braun LT, Vogel F, Zopp S, Marchant Seiter T, Rubinstein G, Berr CM, et al. Whom should we screen for Cushing syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. J Clin Endocrinol Metab. 2022;107:e3723\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"1598_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/0003-4819-147-8-200710160-00006","volume":"147","author":"I Chiodini","year":"2007","unstructured":"Chiodini I, Mascia ML, Muscarella S, Battista C, Minisola S, Arosio M, et al. Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med. 2007;147:541.","journal-title":"Ann Intern Med"},{"key":"1598_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s100670170099","volume":"20","author":"P Kann","year":"2001","unstructured":"Kann P, Laudes M, Piepkorn B, Heintz A, Beyer J. Suppressed levels of serum cortisol following high-dose oral dexamethasone administration differ between healthy postmenopausal females and patients with established primary vertebral osteoporosis. Clin Rheumatol. 2001;20:25\u20139.","journal-title":"Clin Rheumatol"},{"key":"1598_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S2213-8587(13)70062-7","volume":"1","author":"N Stefan","year":"2013","unstructured":"Stefan N, H\u00e4ring H-U, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1:152\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1598_CR31","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.jacc.2018.02.055","volume":"71","author":"M Mongraw-Chaffin","year":"2018","unstructured":"Mongraw-Chaffin M, Foster MC, Anderson CAM, Burke GL, Haq N, Kalyani RR, et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018;71:1857\u201365.","journal-title":"J Am Coll Cardiol"},{"key":"1598_CR32","doi-asserted-by":"publisher","first-page":"e8838","DOI":"10.1097\/MD.0000000000008838","volume":"96","author":"H Lin","year":"2017","unstructured":"Lin H, Zhang L, Zheng R, Zheng Y. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity. Medicine. 2017;96:e8838.","journal-title":"Medicine"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01598-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01598-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01598-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T13:04:40Z","timestamp":1729775080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01598-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1598"],"URL":"https:\/\/doi.org\/10.1038\/s41366-024-01598-0","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"24 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. Ethical approval for this study was obtained from the Local Ethics Committee of Diskapi Yildirim Beyazit Training and Research Hospital (approval date: 13.12.2021, number: 126\/04). Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}